Latest From Elekta AB
The global market for prostate cancer diagnostics is expected to see double-digit growth, reaching $460.5m in 2023 and is driven by new technologies, in particular liquid biopsies and new genetic marker tests, according to a new report by Informa's Meddevicetracker.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
Hindsight 20/20 is a Q&A feature where veterans of the medtech industry share career highlights, specific achievements and hurdles they have faced. In this installment, Kevin Brown, global VP of scientific research at radiation therapy specialist Elekta, discusses the challenges of translating scientific ideas into breakthrough technologies that bring value to clinicians and patients. He also addresses his guiding principles for picking winning ideas and his journey bringing to market the world's first integrated high-field MRI and radiotherapy system.
Results of a small clinical trial of tractography-based ventral intermediate nucleus-targeting suggest this MRI-based imaging approach could help improve the outcomes of focused ultrasound brain intervention with InSightec's Exablate Neuro system for the noninvasive treatment of essential tremor.
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Elekta AB
- Senior Management
Richard Hausmann, PhD, Pres. & CEO
Gustaf Salford, CFO
John Lapre, PhD, CTO
Steven Wort , COO
Maurits Wolleswinkel, Head, Potfolio &. Chief Strategy Officer
Ioannis Panagiotelis , PhD, Chief Mktg. & Sales Officer
- Contact Info
Phone: (46) 8 587 254 00
P.O. Box 7593 Stockholm, SE-103 93
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.